论文部分内容阅读
1999年12月至2001年12月,我院联用博尔泰力与拉米夫定治疗慢性乙型病毒性肝炎44例效果满意。现报告如下。 资料与方法:本组HBsAg,HBA、抗HBe、HBV-DNA均为阳性,血清ALT持续波动于正常上限2～5倍达6个月以上,符合2000年10月西安第10次全国病毒性肝炎会议修订的病毒性肝炎诊断标准。入选病例随机分为联合组(博尔泰力+拉米夫定)和对照组(单用拉米夫定)。联合组44例,对照组42例,两组在性别、年龄、病程、病情上无显著差异(P>0.05),治疗期间不加用其它抗病毒药物和免疫调节剂,但均给予常规护肝药
December 1999 to December 2001, our hospital Bortezil and lamivudine treatment of 44 cases of chronic hepatitis B results were satisfactory. The report is as follows. Materials and Methods: The group of HBsAg, HBeAg, anti-HBe, HBV-DNA were positive, serum ALT fluctuations in the normal upper limit of 2 to 5 times for 6 months or more, in line with October 2000 Xi’an 10th National Viral Hepatitis Meeting revised diagnostic criteria for viral hepatitis. Selected cases were randomly divided into combined group (Bortezide + Lamivudine) and control group (lamivudine alone). There were 44 cases in the combination group and 42 cases in the control group. There was no significant difference in gender, age, course of disease and disease between the two groups (P> 0.05). Other antiviral drugs and immunomodulatory agents were not added during the treatment, medicine